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Abstract: Health care spending has risen steadily in most countries, becoming a concern for 
decision-makers worldwide. Commentators often point to new medical technology as the key 
driver for burgeoning expenditures. This paper critically appraises this conjecture, based on an 
analysis of the existing literature, with the aim of offering a more detailed and considered analy-
sis of this relationship. Several databases were searched to identify relevant literature. Various 
categories of studies (eg, multivariate and cost-effectiveness analyses) were included to cover 
different perspectives, methodological approaches, and issues regarding the link between medical 
technology and costs. Selected articles were reviewed and relevant information was extracted 
into a standardized template and analyzed for key cross-cutting themes, ie, impact of technol-
ogy on costs, factors influencing this relationship, and methodological challenges in measuring 
such linkages. A total of 86 studies were reviewed. The analysis suggests that the relationship 
between medical technology  and spending is complex and often conflicting. Findings were 
frequently contingent on varying factors, such as the availability of other interventions, patient 
population, and the methodological approach employed. Moreover, the impact of technology 
on costs differed across technologies, in that some (eg, cancer drugs, invasive medical devices) 
had significant financial implications, while others were cost-neutral or cost-saving. In light of 
these issues, we argue that decision-makers and other commentators should extend their focus 
beyond costs solely to include consideration of whether medical technology results in better 
value in health care and broader socioeconomic benefits.
Keywords: medical technology, health expenditure, health policy, costs
Introduction
Health care spending has risen at rates greater than gross domestic product in most 
OECD countries. In 2009, average health spending reached 9.5% of gross domestic 
product, up from 8.8% in 20081 (Figure 1). During the same time period, average per 
capita spending increased by an average of 3.8% in 2008 and 3.5% in 2009, with public 
spending on health growing at an even faster rate of 4.8% and 4.1%, respectively.1 For 
most countries, rising health expenditure is considered an enduring challenge and one 
that requires a complex balancing act between cost control, affordable and equitable 
access to beneficial treatments, and support for innovation.
A number of factors have been identified as contributors to spending growth, 
including the ageing of populations, increased public demand and expectations, 
personal income growth, rising prices of physician and hospital services (eg, labor 
costs), and inefficiencies in the organization and payment of care. For example, the 
growth in life expectancy has had an obvious yet gradual impact on the demand for 
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health care. Although the use of care depends ultimately 
on the health status of a person and not necessarily on their 
age cohort(s), elderly people use health care more often 
and more intensively than younger populations, with a high 
proportion of costs garnered at the end of life.2 Longer life 
spans, in concert with an increase in unhealthy lifestyles, 
have also contributed to an increased prevalence of disease, 
particularly chronic conditions such as obesity, diabetes, and 
cancer. Greater prevalence of chronic conditions are likely to 
increase spending both through an increase in treated preva-
lence (ie, number of cases treated) and the cost of treatment 
(ie, spending per case).
However, analysts often point to advances in medical 
technology and their diffusion across health systems as the 
principal driver for burgeoning expenditures.3–10 This paper 
critically examines this conjecture, based on an analysis of a 
broad range of existing evidence on the relationship between 
medical technology diffusion and health expenditure. We strive 
to focus on medical devices, given the gap in the literature on 
their role in health expenditures, which has predominantly 
centered on pharmaceuticals, and because the sector has grown 
considerably in recent years. Not only are there substantially 
more medical technologies on the market, but they have grown 
increasingly sophisticated.
The paper is structured as follows. We first outline the 
methods used to review the literature, followed by a sum-
mary of the available evidence. The paper then discusses the 
complexities inherent to ascertaining the impact of technol-
ogy on spending, including some of the methodological 
challenges associated with demonstrating and quantifying 
this link. Based on the analysis, we close by arguing that 
while the impact of medical technology on rising costs is 
an important concern and area of inquiry, attention should 
also be focused on exploring whether investments in medical 
technology result in better value, as measured by therapeutic 
benefit, cost-effectiveness, and other important outcomes 
(eg, quality of life, improved productivity) in health care, 
and under which conditions technologies allow for the most 
effective and efficient use of available health care resources. 
We offer some general suggestions for what might be done 
to support this end.
Materials and methods
A literature review was conducted to explore the  current 
 evidence base on the relationship between medical 
 technology and health care expenditures. Unlike previous 
studies in this area, we considered a wide range of literature 
to ensure adequate coverage of different methodological 
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approaches and ideological perspectives for assessing this 
 relationship. The categories of literature included in the 
search and review included general and descriptive analyses, 
policy analyses, literature reviews, multivariate analyses, 
cost-effectiveness analyses, and cost impact studies of 
 specific technologies. Table 1 presents and describes the 
various study types included in the review.
Key databases, including PubMed, EMBASE, MEDLINE, 
and EconLit, were searched to identify relevant literature. 
The search terms employed to identify relevant literature 
included “technolog* AND (expenditure OR cost) AND 
(health OR healthcare)”, and “medical AND technolog* 
AND  (expenditure OR cost)”.
To identify relevant cost-effectiveness analyses across 
all medical technologies would be a considerable task. 
Therefore, we took advantage of two previously completed 
systematic reviews of economic evaluations of medi-
cal devices in the cardiology and orthopedic sectors, the 
two most significant markets for therapeutic devices.11 
In these reviews, we used the National Health Service 
Economic Evaluation Database12 for the searches, which 
contains structured reviews (abstracts) of full economic 
evaluations of health care treatments and programs. In 
these two previously conducted studies, we employed the 
following search terms “cardiology”, “cardiac rhythm 
management”, “cardiovascular”, “coronary stents”, 
“cardiac resychronization”, “implantable cardioverter 
defibrillators”, “orthopaedic”, “hip”, “knee”, “shoulder”, 
“ankle”, “elbow”, “arthroplasty”, and “joint”.
All the relevant abstracts were reviewed, from both the 
general literature review and the review of National Health 
Service Economic Evaluation Database. Duplicate and 
irrelevant abstracts were identified and eliminated. Selected 
articles were reviewed according to a data extraction form, 
developed in Microsoft Excel, to standardize the review and 
facilitate subsequent analysis of the collated information. 
The categories of information extraction included: basic 
bibliographic information; publication year; literature type 
(eg, descriptive analysis); study aims; technologies studied; 
study setting; methods employed; outcomes across health, 
costs/expenditures, and cost-effectiveness; and, stated conclu-
sions and implications of the study. The information extracted 
was then analyzed for key themes across the domains inter est 
(ie, impact of medical technology on costs or spending and 
factors influencing this relationship, and the methodological 
challenges noted in measuring such linkages).
A total of 86 studies were included in the review 
(Appendix 1). Table 2 provides a summary of general study 
details. The majority (52%) of studies were more qualita-
tive in nature (eg, descriptive and policy analyses, literature 
reviews), followed by cost-effectiveness (40%) and mul-
tivariate (24%) analyses. In addition, the bulk of studies 
Table 1 Types of studies included in the review
Study type Definition
general and descriptive analyses generally provide an in depth analysis of the main variables or factors affecting health expenditures. Some of 
these studies take a broad approach examining a range of variables, while others focus on a particular issue, 
such as medical technology, on spending. Furthermore, studies vary in whether they examine national-level  
expenditures or take a narrower approach by assessing hospital spending. Most of these studies are qualitative.
Policy analyses Evaluate the impact of different policy interventions (eg, managed care, changes to hospital organization 
or services) and their impact on health expenditures, as well as on mediating factors, such as technology 
diffusion. Other policy studies consider the implications of high expenditures associated with a particular cost 
driver (eg, aging, technological advancement). Analyses can be either qualitative or quantitative in nature.
Literature reviews Assess the current literature on the impact of a particular factor or a broad array of factors on health 
expenditures. This category includes systematic reviews and general literature reviews.
Econometric analyses Typically entails multivariate studies, which examine multiple variables and their effects (and interrelationships) 
on health expenditures. These studies employ three methodological approaches most frequently, including the 
“residual” approach, the “proxy” approach, and case studies of specific technologies. The residual approach 
measures the impact of certain demographic and economic factors (eg, population aging) known to affect 
health expenditures and then attributes the unexplained portion of spending growth to medical technology. 
The proxy approach is an indirect method, which employs a measurable proxy indicator for technological 
change (eg, spending on research and development, time, patents) to explain health care spending trends. The 
case study approach examines how a specific technology and the associated changes in clinical practice affect 
spending on specific types of patients, conditions, or settings.
Cost-effectiveness analyses Assess the cost and clinical benefits of a given technology. Such studies seek to ascertain the value for money 
of a particular intervention. This approach often entails combining clinical benefit with quality of life in a single 
generic measure of health gain, the quality-adjusted life year, in a cost-utility analysis.
Cost impact studies Evaluate the impact of specific technologies or policies on costs, either at one point in time or over time.
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were published within the last ten years (77%) and focused 
on the US (52%). With the exception of cost-effectiveness 
and cost impact studies examining specific medical devices, 
most studies (52%) examined medical technology in general, 
which in some cases included some combination of drugs, 
devices, diagnostics, or procedures.
Results
Although technological innovation is of great significance 
in health care13,14 and has been claimed to be a key driver of 
health spending, the review highlighted that research mea-
suring the potential contributions of medical technology to 
rising health care costs has been relatively sparse. One pos-
sible reason for this neglect, and the predominant reliance 
on more descriptive or qualitative analyses among available 
studies, is that technology itself and its possible implications 
on health expenditures are insufficiently understood. Other 
reasons center on the often limited data available to explore 
this relationship and the complexities of measuring such 
associations, which we discuss further below.
The available evidence that does exist suggests that, in 
general, new medical technology is an important determinant 
in rising health care expenditures. Of the studies reviewed that 
attempted to quantify this relationship, mainly econometric 
studies, the overall impact (ie, proportion of the cost increase) 
ranges from approximately 25% to 75%, averaging at about 
50%7,9,10,14–19 (Table 3).
While much of the quantitative evidence indeed substanti-
ated the cost-increasing effect of new technology overall, the 
broader spectrum of evidence (eg, cost-effectiveness studies, 
descriptive analyses) suggests that the relationship between 
technological advances and health care expenditure is not 
straightforward or static. Rather, it should be understood as 
being complex, with a wide range of potential intervening 
factors that change and shift the dynamic of the association, 
depending on the particular circumstances.
For example, this relationship often differed across 
technologies, with some exerting more upward pressure on 
health care expenditure than others. Of 16 diseases (and sub-
groups) studied by Scitovski20 in a case study, new technology 
decreased costs in eight cases, increased costs in seven, and 
in one case had neutral effects. The use of “low-tech” tech-
nologies such as electrocardiography, laboratory tests, and 
x-rays stabilized or increased costs at a moderate pace, while 
the use of complex or sophisticated technologies and pro-
cedures such as cesarean section, new treatment modalities 
for breast cancer, and coronary bypass surgery substantially 
increased costs. In another case study, Bryan et al21 found 
that technology that introduces computer-based information 
networks for imaging archiving increased annual hospital 
costs by 1.8%. A Congressional Budget Office6 review of the 
available economic literature highlighted particular areas of 
technology advancement that has been accompanied by more 
spending, including revascularization for coronary artery 
disease, diagnostic imaging, and joint replacement.
Whether a particular technology increases or decreases 
costs depends on whether a given technology: substitutes 
Table 3 Contributions of selected factors to growth in health care spending
Di Matteo15 Jones16 Pricewaterhouse 
Coopers7
Smith 
et al19
Peden and 
Freeland17
Cutler9 Newhouse10
Life expectancy/aging ∼9% * 15%** 2% 6%–7% 2% 2%
Administrative costs * * 15%*** 3%–10% * 13% *
Changes in financing * * * 10% 4%–5% 10% 10%
Personal income growth 9%–20% * * 11%–18% 14%–18% 5% ,23%
Health care prices * * 18% 11%–22% * 19% *
Technology ∼65% 50%–75%25% 38%–62% 70%–75% 49% .65%
Notes: *not estimated; **included aging, but also “front page treatments” (ie, media coverage drives demand for expensive treatment), increased preventive and diagnostic 
activity, and consumers moving away from less expensive managed care products; ***included government mandates (including new mandated benefits) and federal and state 
regulatory requirements.
Table 2 Characteristics of the reviewed literature
Study characteristics
Type of study Number Year Number
general/descriptive analysis 12 1980–1985 1
Policy analysis 8 1986–1990 2
Literature review 4 1991–1995 5
Multivariate analysis 21 1996–2000 12
Cost-effectiveness analysis 34 2001–2005 37
Cost impact study 7 2006–2010 29
Technology studied Number Study setting Number
general health technology 27 US 45
Specific medical devices 41 Europe 21
Specific drugs 3 OECD 5
Combination of specific drugs, 
devices, and/or services
7 Canada 5
Other* 8 Other** 10
Notes: *Articles that focused on cost containment policy effects and general economic 
trends; **articles that did not focus on any one country, or did not specify.
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for an existing service; expands the number of treatable 
conditions, in that it allows providers to treat conditions they 
previously could not treat or could not treat effectively or 
aggressively; intensifies level of use of the technology for the 
same condition; impacts the delivery of care (eg, improves 
the capacity of the system to treat more patients); broadens 
the definition of diseases; and extends life, for which each 
patient bears (or induces) additional years of health care 
consumption.6,17,22–25
For instance, with regards to increasing the indications 
and applications of the innovations, the initial use of imag-
ing diagnostics (eg, x-rays, computed tomography, magnetic 
resonance) was initially targeted to specific organs and 
functions, but their application has extended to almost every 
part of the human body, resulting in increased spending.26 
Further, some new technologies may allow lower unit costs 
(ie, treatment becomes cheaper) or cause less discomfort or 
complications, thereby offering the potential for cost savings. 
However, these benefits may lead to increased provision of 
services to persons who, without the new technology, may not 
have undergone a particular treatment. Therefore, when the 
cost savings per case are offset by the increased number of 
procedures, these technologies will result in increased costs 
in the aggregate, but will almost certainly also increase the 
total benefits from the care provided. Chernew et al27 found 
this was the case with regard to introduction of laparoscopic 
techniques at the beginning of the 1990s in the US. Of course, 
new technology can also help extend life (in patients with 
life-threatening or chronic conditions), which may result 
in higher spending due to extended years of health care 
 utilization. However, in parallel, a given technology may also 
allow individuals to live those additional years with greater 
quality of life or in an improved health state, which could 
bring potential cost-savings and/or broader social benefits.
In contrast, those technologies that have a substitutive 
effect, thereby reducing treatment with older technology, 
eg, use of percutaneous transluminal coronary angioplasty 
(PTCA) and coronary artery bypass grafting (CABG), may 
facilitate reductions in spending, even if treatment expan-
sion follows.25,26 For example, PTCA outcomes improved 
through the introduction of coronary stents, leading to 
reduced occurrence of restenosis, heart attacks, emergency 
CABG, and mortality. Consequently, the procedures had 
become highly substitutable with CABG and for patients with 
severe coronary artery disease. While the growth of PTCA 
resulted in higher costs, this has been offset over time by the 
substitution of PTCA for CABG. Therefore, by metrics of 
costs, the diffusion of some new technologies can increase 
spending rapidly at first as it treats those who went without, 
and less rapidly over time as technology substitutes for more 
expensive existing treatments.28,29
Moreover, the impact of technology on costs varies 
depending on the circumstances (eg, patient population, 
placement in treatment pathway) within which a given 
therapy is used. For example, several cost-effectiveness 
analyses on drug-eluting stents have demonstrated that use of 
these devices increased per patient treatment costs compared 
with standard balloon angioplasty.30–32 However, if used in 
medium-risk to high-risk patients, drug-eluting stents could 
be cost-neutral31,32 or even cost-saving.30
There are also organizational, economic, and social con-
siderations that influence the link between new technology 
and spending and arguably interplay with the aforementioned 
factors. For example, impacts on costs may be affected by 
how the technology is administered or impacts the delivery 
of care, because some innovations may lead to an increased 
use of medical personnel, material supplies, or training, par-
ticularly if they employ a new technique or procedure, while 
others may reduce staff or time requirements or shift care to 
less costly settings of care (eg, inpatient to outpatient).33,34 In 
particular, some technologies may improve the efficiency of 
care delivery by reducing procedure time, length of stay, or 
number of hospitalizations, thereby increasing the capacity 
of the hospital to treat additional patients. Overall costs may 
rise as a result, but such outlays will likely result in improved 
health outcomes for a greater number of patients.
Finally, technological advancements may generate con-
sumer demand for care (and, perhaps more intense, costly 
services, even if not cost-effective), as well as the demand 
for insurance.17,27,35,36 At the same time, expanding insurance 
provides increased incentives to develop new technologies.22 
Some analysts maintain that such incentives contribute to long-
term growth in expenditure, because the development costs of 
these products must be recouped by industry (leading to higher 
prices).6 Although much of this evidence originates from the 
US, Barros and Martinez-Giralt37 also found that payment 
systems affect the rate of technology adoption and utilization in 
European systems. National procurement policies and practices 
may also influence their diffusion into the health system and 
the costs associated with adoption. For example, use of more 
centralized purchasing strategies (eg, local or regional procure-
ment consortiums) or value-based purchasing in Europe and 
elsewhere, where payment is directly linked to the quality and 
efficiency of a new technology, may reduce spending.38,39
In relation to this point, there are important differences 
between countries and their respective health systems that 
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influence the adoption and diffusion of new technologies. For 
instance, technological change often results from incentives 
in the health care system. Given that incentive structures dif-
fer across countries, technology influences spending differ-
ently across jurisdictions.40 Lambooij et al41 assert that lower 
resourced countries encourage diffusion of innovations that 
enhance efficiency, whereas better resourced jurisdictions 
encourage diffusion of complex, expensive technologies.
Discussion
The results of our review suggest that medical technology 
does have a significant role in health care expenditures, albeit 
a dynamic and complex one. However, there are limitations 
to the methodological approaches used in the available pub-
lished literature, which introduce challenges to arriving at a 
clear assessment of such dynamics. For example, in terms of 
quantifying this link, the residual approach4,10,17 can yield a 
reasonable indirect approximation of how medical technology 
relates to long-term growth in total health expenditure, but it 
can be sensitive to assumptions regarding the effects of other 
related factors (eg, personal income, health insurance coverage, 
technology development) and the dynamics between them.6,18 
This frequently leads to an overestimation of the effect of 
technology on spending. Another common method, ie, the 
proxy approach,14,15 is only as good as the proxy indicator 
used to assimilate the impact of technology on spending. The 
use of time as a proxy measure for technological change, for 
example, not only captures such changes, but may also encap-
sulate variations in policy, patient experiences, preference, and 
expenditures.15
Another method, ie, the case study approach,25,26 is use-
ful to explain the impact of certain medical technologies on 
health care costs, but there are problems of sampling and it 
is difficult to generalize to an aggregate or national level.6,19 
Consequently, most analysts using this approach have focused 
on the most significant conditions (eg, prevalent, contributing 
to high levels of mortality or disability), such as heart disease. 
These technical issues also characterize cost-effectiveness 
and cost impact analyses.42–45
In addition to the limitations noted with individual 
approaches, there are technical issues shared across the 
various methods. Firstly, the results are frequently based 
on aggregate level data that are often subject to potential 
endogeneity and omit variable bias.46 Secondly, as intimated 
above, several of these methods can depend on relatively 
simplified models dealing with highly complicated and inter-
related parameters16 and can only arrive at conclusions about 
the collective effect of technology on health care spending, 
not on the contributions of specific technologies. Different 
types of technologies (eg, drugs versus medical devices) 
arguably impact health spending differently, particularly in 
terms of the associated changes in clinical practice that fol-
low their adoption. For example, a recent study47 estimated 
that medical devices account for a relatively small share of 
national health expenditures (3%–5%), which have risen 
only slightly over the last 20 years, ie, a trend different from 
that of pharmaceuticals. Thirdly, across both quantitative 
and qualitative approaches, capturing the economic (and 
social) complexities surrounding the use of technology can 
be challenging, because it generally necessitates a complete 
understanding of the manner and magnitude of change in the 
clinical management pathway associated with treatment and 
follow-up. This process can occur over extended periods of 
time, and can have varying resource costs that can be both 
easy and difficult to measure.48
Available studies are often focused on a narrow time 
window and the specific duration of the life cycle for a 
technology. Therefore, results from studies with longer or 
different time periods could vary. For instance, the price of 
medical technologies generally decreases over time, which 
would not be captured in shorter-term studies or those that 
happen to examine a given technology(s) close to initial 
launch. Similarly, technological advances occur simultane-
ously with changes in other factors that affect health care 
spending, such as personal income and health financing 
systems, which make it difficult to identify causality reliably, 
and exactly how technology itself affects spending growth. 
Finally, current methods cannot effectively demonstrate the 
cost impact that would result if availability of technology 
were reduced or eliminated. In the short-term, cost-savings 
may be achieved, while limited access to technology may 
result in higher costs in the long term due to the presence of 
disease that was not adequately treated owing to reliance on 
older, less-effective technologies or a complete lack of viable 
treatment alternatives.
Therefore, while examining the role of medical technol-
ogy in rising health expenditures is indeed an important area 
of inquiry, it is largely an incomplete exercise, due to some 
of the noted methodological issues, and also because most 
new technological innovations are cost-increasing. Even if 
a given technology increases costs, it may increase benefits 
by an even greater amount. In addition, the same  technology, 
applied in different settings, or in different groups of patients, 
could be cost-effective in some instances and not in  others. 
Consequently, alongside simply examining costs, it is perhaps 
more productive to assess whether the additional benefits 
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resulting from the use of the technology justify any increase 
in costs and under which circumstances technologies deliver 
greater value in health care. That is, are the resulting spending 
levels reflected in more effective, cost-effective, and higher 
quality health care?
Several studies from the review indicate that, on average, 
increases in spending as a result of technological advances 
have provided reasonable value. For example, Cutler et al49 
found that from 1960 to 2000, average life expectancy 
increased by 7 years, 3.5 years of which were attributable 
to improvements in health care. Comparing the value of a 
year of life (anywhere from $50,000 to $200,000) with the 
finding that each year of increased life expectancy cost about 
$19,900 in health spending, they conclude that the increased 
spending, on average, had been a worthwhile investment. 
Similar conclusions were arrived at by Cutler and McClellan25 
and Skinner et al50 in examining technological innovation 
in cardiac care. The former, for example, demonstrated that 
the use of new technology helped to increase the average 
coronary patient’s life expectancy by one year (valued at 
$70,000 per case), while treatment costs increased $10,000 
per case (4.2% per year), for a net benefit of $60,000 per 
case. In addition, as previously discussed, cost-effectiveness 
analyses of particular medical devices demonstrate value 
for money (as measured by cost per quality-adjusted life 
year) and in some limited cases, cost savings.30,31,42,51–53 On a 
broader level, Fuchs and Sox54 surveyed physician percep-
tions of the importance of and value brought by various 
areas of technological innovation, with magnetic resonance 
imaging and computed tomographic scanning, angiotensin-
converting enzyme inhibitors, balloon angioplasty, statins, 
and mammography all rated highly.
Before concluding, it is important to note a few limita-
tions to this study. Firstly, while we strove to select and 
review only studies focused on medical technology, some 
studies, particularly certain types of econometric studies, 
looked at technology collectively. Therefore, for those stud-
ies, we were unable to distinguish the relative contribution of 
different types of technology (eg, drugs versus devices) to the 
proportion of spending attributed to technological innovation. 
Secondly, we focused our review of cost-effectiveness 
studies only on selected cardiology and orthopedic devices. 
Nevertheless, these particular sectors are arguably important 
markets and those most likely to have a cost impact.
Conclusion
Major technological advances in medical science have 
allowed health care providers to diagnose and treat illnesses 
in ways that were previously impossible. In general, such 
developments have tended to increase health care spending, 
which has been seen as an important policy concern, espe-
cially considering ever-limited health care budgets.
However, examining the link between medical technology 
and health expenditures is only one part of the picture. In 
order to understand better the dynamics between innovation 
and spending, it is important to assess whether and under 
what circumstances do investments in medical technology 
result in better value in health care. As Cutler and McClellan25 
assert, “it does not necessarily follow that technology change 
is therefore bad … costs of technology need to be compared 
with benefits before welfare statements can be made”. Given 
the current global economic situation, it is ever more impor-
tant to ensure that we are attaining good value for money 
from the technologies developed.
To be sure, the question of whether medical technologies 
result in added value to the health care system is, of course, also 
difficult to answer. It depends on our ability to determine the 
value of output from the health services sector, and placing a 
value on longer or better quality of life is difficult to appraise. 
As a starting point, much more comparative research is needed 
to understand better which technologies work best and are 
most cost-effective, and under what circumstances. Indeed, 
as previously discussed, some of the cost-increasing effects of 
technology arise from inappropriate use, where new treatments 
are offered to patients for whom there is none to little clinical 
benefit. Current efforts to support comparative effectiveness 
research in the US and health technology assessment in Europe 
and elsewhere may help to foster these aims. However, it is 
important to note that medical technologies introduce unique 
technical challenges to health technology assessment or com-
parative effectiveness research, so assessment methods should 
adequately account for or be developed to accommodate such 
aspects.55 Moreover, in addressing questions of value, such 
research should strive, where possible, to assess a broad range 
of potential benefits beyond clinical or therapeutic benefit, 
including value for money, higher quality of care, improved 
quality of life, greater efficiency in care delivery (eg, reduced 
length of stay, shifting care from inpatient to outpatient settings), 
and enhanced ability to work or return to work.
If the evidence generated from such research is to have 
an impact on health care spending, it should be used to 
inform policy and practice. As such, comparative effective-
ness research and health technology assessment should be 
used to help reward and support the introduction of tech-
nologies into practice that confer therapeutic benefit and 
reasonable value for money, either through use in coverage 
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and payment policies, insurance benefit design, or practice 
guidelines. Conversely, use of low-value interventions 
should be disincentivized through disinvestment or limita-
tion on their use. Such strategies should be coupled with a 
greater emphasis on evidence-based delivery of care (eg, 
aligning appropriate financial incentives for providers and 
consumers), which might further reduce expenditure lev-
els if such incentives support greater use of cost-effective 
services.6 However, in parallel, it will be important to 
monitor carefully the impact of such policy levers in order 
to ascertain the best way to control costs without denying 
the benefits of new innovation. In addition, such measures 
need to be coupled with other policies and practices to 
address some of the other drivers of health spending, 
including initiatives to support healthy aging and improve 
coordination of care for the chronically ill. Finally, given 
our ever-limited health care resources, it would be prudent 
to debate the opportunity costs of funding new (and increas-
ingly expensive) technologies. Even in cases where medical 
technologies are cost-effective, available resources may 
be better allocated to other equally or more cost-effective 
investments outside of the health care sector, such as the 
environment or education.
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